'%3e%3cpath%20d='M34.1406%205.85938C30.3906%202.10547%2025.3047%200%2020%200C14.6953%200%209.60938%202.10547%205.85938%205.85938C2.10938%209.61328%200%2014.6953%200%2020C0%2025.3047%202.10547%2030.3906%205.85938%2034.1406C9.61328%2037.8906%2014.6953%2040%2020%2040C25.3047%2040%2030.3906%2037.8945%2034.1406%2034.1406C37.8906%2030.3906%2040%2025.3047%2040%2020C40%2014.6953%2037.8945%209.60938%2034.1406%205.85938ZM37.0117%2023.543H31.1602V13.5391H27.6328V19.9414C28.1211%2020.6914%2028.3711%2021.582%2028.3711%2022.5625V22.625C28.3711%2023.668%2028.1172%2024.6055%2027.6328%2025.4297V26.6094H36.082C33.4883%2032.9375%2027.2891%2037.3789%2020.0039%2037.3789C10.3711%2037.3789%202.62109%2029.6289%202.62109%2020C2.62109%2010.3711%2010.3711%202.62109%2020%202.62109C29.6289%202.62109%2037.3789%2010.3711%2037.3789%2020C37.3789%2021.1484%2037.2617%2022.2656%2037.0508%2023.3477C37.0391%2023.4141%2037.0234%2023.4766%2037.0117%2023.543Z'%20fill='white'/%3e%3cpath%20d='M22.3086%2018.5352C20.4336%2018.125%2019.9531%2017.8398%2019.9766%2017.1836V17.1406C19.9766%2016.6992%2020.3477%2016.2148%2021.4023%2016.2148C22.582%2016.2148%2023.8867%2016.6797%2025.0781%2017.4766L26.8516%2015.0195C25.4453%2013.8906%2023.707%2013.3398%2021.5547%2013.3398C18.5195%2013.3398%2016.4375%2015%2016.4063%2017.4766V17.5352C16.3633%2020.2617%2018.5859%2020.9805%2021.293%2021.6016C23.0391%2021.9766%2023.5703%2022.3164%2023.5703%2022.9609L23.5469%2022.9766C23.5469%2023.3906%2023.2578%2023.7031%2022.7852%2023.8359C22.5742%2023.9062%2022.1289%2023.9727%2021.5156%2023.9727C20.7617%2023.9727%2019.7539%2023.8633%2018.6328%2023.4844C18.0898%2023.2891%2017.4727%2023.0039%2016.8047%2022.6133L20.1406%2026.625C20.2813%2026.6602%2021.0977%2026.8516%2021.7734%2026.8516C25.0039%2026.8516%2027.0859%2025.2461%2027.1094%2022.6328V22.5703C27.1602%2020.1133%2025.2148%2019.1719%2022.3086%2018.5352Z'%20fill='white'/%3e%3cpath%20d='M5.24219%2013.5664V26.6133H8.75391V23.7578L10.2969%2021.9531L14.2031%2026.6133H18.3867L12.3555%2019.5195L17.4023%2013.5664H13.4531L8.75391%2019.0586V13.5664H5.24219Z'%20fill='white'/%3e%3c/g%3e%3cdefs%3e%3cclipPath%20id='clip0_97_2430'%3e%3crect%20width='40'%20height='40'%20fill='white'/%3e%3c/clipPath%3e%3c/defs%3e%3c/svg%3e)
Lifestyle Features
Most Recent
In the kitchen, Gabby finds joy after years in foster care
VideoAshley Moser, KSL | Posted Sept. 30 - 4:58 p.m. | Save Story
Sixteen-year-old Gabby, who has lived in five foster homes, finds comfort in cooking and hopes to find a caring family to call her own.
Regeneron weight-loss drug halves muscle loss in combination with Novo's semaglutide in trial
Sriparna Roy, Reuters | Updated Sept. 30 - 4:30 p.m. | Save Story
An experimental weight-loss drug being developed by Regeneron used in combination with Novo Nordisk's semaglutide reduced the loss of muscle mass by 50% compared with the loss seen with semaglutide alone in a study of patients with obesity, according to data being presented at a medical meeting.
Experimental Lilly combination drug tops Zepbound in weight-loss trial
Patrick Wingrove, Reuters | Updated Sept. 30 - 2:30 p.m. | Save Story
Eli Lilly said on Wednesday its experimental combination weight-loss drug outperformed its blockbuster Zepbound in a head-to-head trial, intensifying the competition with Danish rival Novo Nordisk for new, more effective obesity therapies.
Walgreens-owner Sycamore nears $9 billion sale of Boots, WSJ reports
Reuters | Updated Sept. 30 - 2:14 p.m. | Save Story
Walgreens-owner Sycamore Partners is close to a deal to sell British pharmacy chain Boots to the Weston family for about $9 billion, the Wall Street Journal reported on Wednesday, citing people familiar with the matter.
Merck's experimental skin disease drug succeeds in mid-stage study
Sahil Pandey, Reuters | Updated Sept. 30 - 9:22 a.m. | Save Story
Merck said on Wednesday its experimental drug significantly reduced inflammatory skin lesions in patients with a chronic skin disease, meeting the main goal of a mid-stage study.
Factbox-Weight-loss drug developers line up to tap lucrative market as competition heats up
Reuters | Updated Sept. 30 - 8:45 a.m. | Save Story
The weight-loss drug market is booming, with biotech firms racing to capture a slice of the fast-growing sector dominated by Novo Nordisk and Eli Lilly.
Cigna expects $3 billion in cost savings by 2030
Reuters | Updated Sept. 30 - 8:40 a.m. | Save Story
(Corrects headline and paragraph 1 to clarify that Cigna is not investing $3 billion, but expecting that amount in cost savings by 2030)
Factbox-Major drugmakers turn to China for licensing deals
Reuters | Updated Sept. 30 - 6:17 a.m. | Save Story
Novo Nordisk said on Tuesday it will pay up to $2.6 billion to Jiangsu Hengrui Pharmaceuticals for the rights to an experimental weight-loss pill, making it the latest drugmaker to license China-developed medicines.
Patients switching to Novo Nordisk's Wegovy pill from shots lose more weight in real-world study
Patrick Wingrove, Reuters | Updated Sept. 30 - 3:57 a.m. | Save Story
Patients who switched from weight-loss injections to Novo Nordisk's daily Wegovy pill continued to lose weight, according to data unveiled at a medical meeting on Wednesday, as the Danish drugmaker seeks to defend its lead over US rival Eli Lilly in the market for oral obesity treatments.
Gerresheimer's quarterly sales recovery boosts shares
Reuters | Updated Sept. 30 - 2:01 a.m. | Save Story
Gerresheimer reported a sequential recovery in its second-quarter revenue on Wednesday, sending its shares 8% higher in early trading, as demand for its drug delivery devices boosted sales.
Lundbeck expresses interest in buying Xeris, Bloomberg News reports
Reuters | Updated Sept. 29 - 4:36 p.m. | Save Story
Danish drugmaker H Lundbeck A/S has expressed interest in acquiring Chicago-based Xeris Biopharma, Bloomberg News reported on Tuesday, citing people familiar with the matter.
Lilly's experimental drug cuts weight by 21% in diabetes trial
Reuters | Updated Sept. 29 - 4:14 p.m. | Save Story
Eli Lilly said on Tuesday its experimental drug helped adults with type 2 diabetes and obesity lose an average of nearly 21% of their body weight in a late-stage clinical trial.
UniQure plunges as Huntington's trial data disappoints investors
Christy Santhosh, Reuters | Updated Sept. 29 - 4:11 p.m. | Save Story
UniQure said its gene therapy for Huntington's disease fell short of the goal of slowing disease progression significantly after four years, sending its US-listed shares plummeting 40% on Tuesday.
Novo says Ozempic shows lower risk of cardiovascular events compared to Lilly's Mounjaro
Reuters | Updated Sept. 29 - 3:49 p.m. | Save Story
Novo Nordisk said on Tuesday a real-world study found that adults with type 2 diabetes who took an escalated dose of its diabetes drug, Ozempic, had a lower risk of major cardiovascular events compared to those who switched to Eli Lilly's Mounjaro.
Utah sled hockey program reaches championship in 3rd year
Tyrese Boone, KSL | Posted Sept. 29 - 8:48 a.m. | Save Story
What started as a new adaptive sports program in Utah three years ago already reached a championship game as the Utah Mammoth's sled hockey team's annual tournament this weekend.
US CDC confirms two measles-related deaths in 2026
Siddhi Mahatole, Reuters | Updated Sept. 29 - 8:31 a.m. | Save Story
The US Centers for Disease Control and Prevention on Tuesday confirmed a second measles-related death in the country this year, as cases continue to rise across the United States.
Lilly touts Foundayo advantage over Novo's Ozempic pill in diabetes analysis
Reuters | Updated Sept. 29 - 8:07 a.m. | Save Story
Eli Lilly said its oral obesity drug, Foundayo, offers greater weight loss and better blood sugar control than a higher dose of Novo Nordisk's Ozempic pill in adults with type 2 diabetes, citing data from existing studies.
Church of Jesus Christ unveils new Temple Square in general conference special
VideoCarole Mikita, KSL | Updated Sept. 29 - 8:06 a.m. | Save Story
The Salt Lake Temple has undergone extensive renovation, and so has Temple Square. A documentary on the project runs between sessions of general conference Sunday at noon.
